Minnesota Epilepsy Group, P.A. is a clinical research site located in Saint Paul, Minnesota, United States 55102.
Crixeo Health Trust Score: 75/100 (FAIR). This profile has not yet been claimed by the site owner.
Minnesota Epilepsy Group, P.A. has participated in 8 clinical trials.
Therapeutic areas: 15q Duplication Syndrome, CDKL5 Deficiency Disease, Seizures.
Sponsors: Takeda, GlaxoSmithKline, Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc..
Trust Score: 75/100. Verification status: Crixeo Accredited. Patient reviews: 0. Complaints: 0.
Minnesota Epilepsy Group, P.A. has a Crixeo Trust Score of 75/100 (FAIR). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.
Minnesota Epilepsy Group, P.A. has 8 clinical trials on record. Their work covers 15q Duplication Syndrome, CDKL5 Deficiency Disease, Seizures.
Yes — Minnesota Epilepsy Group, P.A. holds Crixeo Accreditation, the quality standard for clinical research sites. Accredited sites have verified compliance documents, strong patient reviews, and sponsor transparency.
Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.